[EN] POLYOXAZOLINE ANTIBODY DRUG CONJUGATES<br/>[FR] CONJUGUÉS ANTICORPS-MÉDICAMENT DE POLYOXAZOLINE
申请人:SERINA THERAPEUTICS INC
公开号:WO2016019340A1
公开(公告)日:2016-02-04
In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.
HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR
申请人:Gai Yonghua
公开号:US20090123423A1
公开(公告)日:2009-05-14
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof:
which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
Autoxidation of N-alkylamides. Part I. N-Acylamides as oxidation products
作者:M. V. Lock、B. F. Sagar
DOI:10.1039/j29660000690
日期:——
Products of the thermal and photosensitised autoxidation of N-alkyl- and NN-dialkyl-amides have been identified. N-n-Alkylamides yield principally N-acylamides, primary amides, and N-formylamides, as a result of initial abstraction of a hydrogen atom from the carbon adjacent to nitrogen. Formation of N-formylamides, and of N-acylamides from N-s-alkylamides, involves C(1)–C(2) bond scission in an N-alkyl
[EN] AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON<br/>[FR] COMPOSÉS D'AMINO-PYRIMIDINE EN TANT QU'INHIBITEURS DE TBKL ET OU D'IKK EPSILON
申请人:MYREXIS INC
公开号:WO2011046970A1
公开(公告)日:2011-04-21
The invention relates to certain amino-pyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).
Abstract In the present work we investigated the conformations of some N -mono-substituted propanamides of general formula CH 3 CH 2 CONHR, wherein R is chosen from n -(C 1 C 9 )alkyl, cyclo(C 3 C 6 )alkyl, some branched (C 3 C 6 )alkyl or phenyl. The amides were synthesised by the well known Schotten-Baumann reaction—acylation of the corresponding amines with propionyl chloride. On the basis of